Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 64

1.

Peptide-MHC-based nanovaccines for the treatment of autoimmunity: a "one size fits all" approach?

Clemente-Casares X, Tsai S, Yang Y, Santamaria P.

J Mol Med (Berl). 2011 Aug;89(8):733-42. doi: 10.1007/s00109-011-0757-z. Epub 2011 Apr 16. Review.

PMID:
21499734
[PubMed - indexed for MEDLINE]
2.

Analysis of MHC-presented peptides: applications in autoimmunity and vaccine development.

Chicz RM, Urban RG.

Immunol Today. 1994 Apr;15(4):155-60. Review.

PMID:
7515244
[PubMed - indexed for MEDLINE]
3.

Use of MHC II structural features in the design of vaccines for organ-specific autoimmune diseases.

Moustakas AK, Papadopoulos GK.

Curr Pharm Des. 2009;15(28):3262-73. Review. Erratum in: Curr Pharm Des. 2009;15(36):4191.

PMID:
19860675
[PubMed - indexed for MEDLINE]
4.

Autoimmune diabetes: the role of T cells, MHC molecules and autoantigens.

Durinovic-Belló I.

Autoimmunity. 1998;27(3):159-77. Review.

PMID:
9609134
[PubMed - indexed for MEDLINE]
5.

[MHC tetramers: tracking specific immunity].

Kosor E, Gagro A, Drazenović V, Kuzman I, Jeren T, Rakusić S, Rabatić S, Markotić A, Gotovac K, Sabioncello A, Cecuk E, Kerhin-Brkljacić V, Gjenero-Margan I, Kaić B, Mlinarić-Galinović G, Kastelan A, Dekaris D.

Acta Med Croatica. 2003;57(4):255-9. Review. Croatian.

PMID:
14639858
[PubMed - indexed for MEDLINE]
6.

Antigen processing: a critical factor in rational vaccine design.

Yewdell JW, Bennink JR.

Semin Hematol. 1993 Oct;30(4 Suppl 4):26-32; discussion 33-4. Review.

PMID:
8303307
[PubMed - indexed for MEDLINE]
7.

Autoimmune tolerance and type 1 (insulin-dependent) diabetes mellitus.

Nossal GJ, Herold KC, Goodnow CC.

Diabetologia. 1992 Dec;35 Suppl 2:S49-59. Review.

PMID:
1478378
[PubMed - indexed for MEDLINE]
8.

Recombinant antibodies with MHC-restricted, peptide-specific, T-cell receptor-like specificity: new tools to study antigen presentation and TCR-peptide-MHC interactions.

Cohen CJ, Denkberg G, Lev A, Epel M, Reiter Y.

J Mol Recognit. 2003 Sep-Oct;16(5):324-32. Review.

PMID:
14523945
[PubMed - indexed for MEDLINE]
9.

T-cells behaving badly: structural insights into alloreactivity and autoimmunity.

Ely LK, Burrows SR, Purcell AW, Rossjohn J, McCluskey J.

Curr Opin Immunol. 2008 Oct;20(5):575-80. doi: 10.1016/j.coi.2008.07.006. Epub 2008 Aug 12. Review.

PMID:
18678247
[PubMed - indexed for MEDLINE]
10.

Molecular mimicry: can epitope mimicry induce autoimmune disease?

Davies JM.

Immunol Cell Biol. 1997 Apr;75(2):113-26. Review.

PMID:
9107563
[PubMed - indexed for MEDLINE]
Free Article
11.
12.

Limited heterogeneity of autoantigens and T cells in autoimmune diseases?

Acha-Orbea H.

Res Immunol. 1991 Jun-Aug;142(5-6):487-90. Review.

PMID:
1754724
[PubMed - indexed for MEDLINE]
13.

The association of MHC with autoimmune diseases: understanding the pathogenesis of autoimmune diabetes.

Ridgway WM, Fathman CG.

Clin Immunol Immunopathol. 1998 Jan;86(1):3-10. Review.

PMID:
9434791
[PubMed - indexed for MEDLINE]
14.

Peptide-MHC complexes assembled following multiple pathways: an opportunity for the design of vaccines and therapeutic molecules.

Corradin G, Demotz S.

Hum Immunol. 1997 May;54(2):137-47. Review.

PMID:
9297532
[PubMed - indexed for MEDLINE]
15.

[The current outlook in the therapy of autoimmune diseases].

Sebastiani GD, Passiu G.

Ann Ital Med Int. 1992 Apr-Jun;7(2):95-101. Review. Italian.

PMID:
1467130
[PubMed - indexed for MEDLINE]
16.

Therapeutic benefits of regulating inflammation in autoimmunity.

Nikoopour E, Schwartz JA, Singh B.

Inflamm Allergy Drug Targets. 2008 Sep;7(3):203-10. Review.

PMID:
18782028
[PubMed - indexed for MEDLINE]
17.

Mechanisms of autoimmunity in the context of T-cell tolerance: insights from natural and transgenic animal model systems.

Siegel RM, Katsumata M, Komori S, Wadsworth S, Gill-Morse L, Jerrold-Jones S, Bhandoola A, Greene MI, Yui K.

Immunol Rev. 1990 Dec;118:165-92. Review.

PMID:
2150401
[PubMed - indexed for MEDLINE]
18.

Antigen-specific immunomodulation via altered peptide ligands.

Bielekova B, Martin R.

J Mol Med (Berl). 2001 Oct;79(10):552-65. Review.

PMID:
11692152
[PubMed - indexed for MEDLINE]
19.

Inhibition of T cell activation by MHC blockade: a possible strategy for immunointervention in autoimmune diseases.

Adorini L.

J Autoimmun. 1992 Apr;5 Suppl A:73-81. Review.

PMID:
1503637
[PubMed - indexed for MEDLINE]
20.

Non-canonical peptides bound to MHC.

Day SL, Ramsland PA, Apostolopoulos V.

Curr Pharm Des. 2009;15(28):3274-82. Review.

PMID:
19860676
[PubMed - indexed for MEDLINE]
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk